We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Read MoreHide Full Article
Key Takeaways
Immunocore is advancing brenetafusp in phase III for first-line advanced cutaneous melanoma.
IMCR is expanding its ImmTAC platform into ovarian, lung and gastrointestinal cancers.
Immunocore is also developing T-cell receptor therapies for infectious and autoimmune diseases.
Immunocore Holdings (IMCR - Free Report) is trying to move beyond the profile of a one-product rare-cancer company. Kimmtrak remains its commercial anchor, but the broader story is increasingly about the company’s T-cell receptor platform.
That shift matters because Immunocore is testing the same core technology across larger solid tumor markets, infectious diseases and autoimmune conditions. The opportunity is wider than metastatic uveal melanoma, but the execution bar is also higher.
Immunocore Extends TCR Therapy Into Solid Tumors
Immunocore’s ImmTAX platform engineers off-the-shelf bispecific T-cell receptor therapies designed to redirect T cells toward diseased cells. In cancer, that gives the company a way to pursue targets inside solid tumors that have historically been difficult to address.
Kimmtrak provided the first commercial validation. Approved in 2022 for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma, the drug is approved in 39 countries and launched in more than 30.
IMCR Makes Brenetafusp Its Next Growth Pillar
Brenetafusp is the lead PRAME-A02 ImmTAC bispecific candidate and the clearest test of Immunocore’s broader oncology ambitions. The registrational phase III PRISM-MEL-301 study is evaluating brenetafusp with Opdivo, from Bristol Myers (BMY - Free Report) , for first-line advanced cutaneous melanoma.
Updated phase I/II data added support for that program. In heavily pretreated HLA-A*02:01-positive advanced melanoma patients, brenetafusp monotherapy showed an 87% six-month overall survival rate, a 57% 12-month overall survival rate and a 52% disease-control rate.
Immunocore Broadens Its Oncology Pipeline
Brenetafusp is also being studied across other tumor types, including ovarian cancer and non-small cell lung cancer. These efforts extend the platform into indications that are far larger than metastatic uveal melanoma and more commercially competitive.
Earlier programs target colorectal cancer and other gastrointestinal cancers. Success across those areas would not only add potential future revenue sources but also strengthen the case that ImmTAC technology can work across multiple solid tumor settings.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
IMCR Moves Into Infectious and Autoimmune Diseases
Immunocore is not limiting its platform strategy to oncology. The company’s pipeline includes clinical-stage infectious disease programs, reflecting an effort to apply T-cell receptor expertise beyond cancer.
The company also plans phase I development of IMC-S118AI, an autoimmune candidate. That move is early, but it signals that Immunocore is testing whether targeted T-cell redirection can support a broader therapeutic business over time.
Immunocore Faces a Competitive Expansion Test
The expansion strategy carries real competitive risk. In larger oncology markets, Immunocore will face checkpoint inhibitors, cell therapies, bispecific antibodies and other T-cell receptor approaches backed by companies with deeper resources and commercial infrastructure.
Bristol Myers already has a major oncology presence through Opdivo, while Adaptimmune Therapeutics (ADAPY - Free Report) is another company centered on engineered T-cell receptor therapies for cancer. That backdrop makes clinical differentiation essential for IMCR.
The bottom line is balanced. Kimmtrak generated $400 million in 2025 revenues, up 29%, and first-quarter 2026 revenues rose 14% to $106.7 million. Still, Kimmtrak remains the company’s only marketed product, keeping diversification important.
A neutral assessment fits the mix of platform potential and execution risk.
View the Zacks #1 Rank List
Image: Bigstock
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Key Takeaways
Immunocore Holdings (IMCR - Free Report) is trying to move beyond the profile of a one-product rare-cancer company. Kimmtrak remains its commercial anchor, but the broader story is increasingly about the company’s T-cell receptor platform.
That shift matters because Immunocore is testing the same core technology across larger solid tumor markets, infectious diseases and autoimmune conditions. The opportunity is wider than metastatic uveal melanoma, but the execution bar is also higher.
Immunocore Extends TCR Therapy Into Solid Tumors
Immunocore’s ImmTAX platform engineers off-the-shelf bispecific T-cell receptor therapies designed to redirect T cells toward diseased cells. In cancer, that gives the company a way to pursue targets inside solid tumors that have historically been difficult to address.
Kimmtrak provided the first commercial validation. Approved in 2022 for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma, the drug is approved in 39 countries and launched in more than 30.
IMCR Makes Brenetafusp Its Next Growth Pillar
Brenetafusp is the lead PRAME-A02 ImmTAC bispecific candidate and the clearest test of Immunocore’s broader oncology ambitions. The registrational phase III PRISM-MEL-301 study is evaluating brenetafusp with Opdivo, from Bristol Myers (BMY - Free Report) , for first-line advanced cutaneous melanoma.
Updated phase I/II data added support for that program. In heavily pretreated HLA-A*02:01-positive advanced melanoma patients, brenetafusp monotherapy showed an 87% six-month overall survival rate, a 57% 12-month overall survival rate and a 52% disease-control rate.
Immunocore Broadens Its Oncology Pipeline
Brenetafusp is also being studied across other tumor types, including ovarian cancer and non-small cell lung cancer. These efforts extend the platform into indications that are far larger than metastatic uveal melanoma and more commercially competitive.
Earlier programs target colorectal cancer and other gastrointestinal cancers. Success across those areas would not only add potential future revenue sources but also strengthen the case that ImmTAC technology can work across multiple solid tumor settings.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote
IMCR Moves Into Infectious and Autoimmune Diseases
Immunocore is not limiting its platform strategy to oncology. The company’s pipeline includes clinical-stage infectious disease programs, reflecting an effort to apply T-cell receptor expertise beyond cancer.
The company also plans phase I development of IMC-S118AI, an autoimmune candidate. That move is early, but it signals that Immunocore is testing whether targeted T-cell redirection can support a broader therapeutic business over time.
Immunocore Faces a Competitive Expansion Test
The expansion strategy carries real competitive risk. In larger oncology markets, Immunocore will face checkpoint inhibitors, cell therapies, bispecific antibodies and other T-cell receptor approaches backed by companies with deeper resources and commercial infrastructure.
Bristol Myers already has a major oncology presence through Opdivo, while Adaptimmune Therapeutics (ADAPY - Free Report) is another company centered on engineered T-cell receptor therapies for cancer. That backdrop makes clinical differentiation essential for IMCR.
The bottom line is balanced. Kimmtrak generated $400 million in 2025 revenues, up 29%, and first-quarter 2026 revenues rose 14% to $106.7 million. Still, Kimmtrak remains the company’s only marketed product, keeping diversification important.
A neutral assessment fits the mix of platform potential and execution risk.
IMCR’s Zacks Rank
Immunocore currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.